Navigation Links
Ritter Pharmaceuticals Hires Dr. Howard Foyt as Executive Vice President, Development & Chief Medical Officer
Date:9/10/2009

LOS ANGELES, Sept. 10 /PRNewswire/ -- Ritter Pharmaceuticals, Inc. (Ritter) has hired Howard Foyt, M.D., Ph.D., FACP as its new Executive VP, Development & Chief Medical Officer. Dr. Foyt brings 13 years of expertise in drug development to Ritter, as the Company prepares to file an IND for its therapy for Lactose Intolerance.

Dr. Foyt will join Ritter's senior management team and oversee the Company's clinical development efforts. Ritter will take advantage of Dr. Foyt's leadership in drug development within big pharma and biotech companies. For the past three years, Dr. Foyt served as VP, Clinical Development and Chief Medical Officer at Metabasis Therapeutics, where he was responsible for five drugs in clinical development over multiple therapeutic areas. Dr. Foyt had previously worked at Pfizer, where he served as Senior Director and Site Head - Diabetes & Obesity, and earlier at Parke-Davis for over ten years participating in the clinical development of multiple drugs mainly in the metabolic disease field. Prior to joining Parke-Davis, Dr. Foyt was on the faculty at the University of Texas Medical Branch, Galveston, TX. He earned his medical degree and Ph.D. in Cell Biology from Baylor College of Medicine. Dr. Foyt completed his residency in internal medicine at Baylor and an endocrinology fellowship at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

"We are thrilled to have Dr. Foyt on our team," said Ritter Pharmaceuticals' President and CEO Andrew Ritter. "His breadth of clinical development and drug development experience will bring a great deal of scientific rigor and creativity to our development plans."

About Ritter Pharmaceuticals

Ritter is committed to the discovery, development and commercialization of innovative therapies for gastrointestinal diseases. The Company's scientific platform of gastrointestinal physiology, metabolism and gut adaptation brings creativity to providing unique therapeutic approaches to a variety of GI diseases, including lactose intolerance, irritable bowel syndrome, Crohn's disease, and ulcerative colitis. Ritter's ultimate goal is to improve digestive health and overall quality of life.

Ritter's first compound, RP-G28, has been developed for the treatment of lactose intolerance. RP-G28 will effectively stand out as the first FDA-approved drug for the treatment of lactose intolerance.

www.ritterpharma.com


'/>"/>
SOURCE Ritter Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reportlinker Adds US and European Radiopharmaceuticals Market Report
2. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
3. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
4. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
5. Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
8. Steven Holtzman Joins Satori Pharmaceuticals Board of Directors
9. Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
10. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2010
11. Isis Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , ... December 05, 2016 , ... The new knee ... individual looking to buy neoprene knee sleeves for lifting and any sport ... focuses heavily on two main aspects to provide a higher quality knee sleeve performance. ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... called the CardioQuick Patch® significantly improves the reproducibility and accuracy of placing precordial ... healthcare settings. , Over the last 60 years, studies have shown that ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... wins "Best Surgical Body Shaping" at the 2016 Anti-Aging & Beauty ... France. , The Aesthetic & Anti-Aging Medicine European Congress (AMEC) brings ...
(Date:12/4/2016)... , ... December 04, 2016 , ... Responsible dental care ... must brush properly to achieve optimal results. This important necessity inspired an inventor from ... for a way to ensure that people break or avoid bad techniques of brushing ...
(Date:12/2/2016)... Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... lien basis to help personal injury victims find high quality medical care. When the ... Los Angeles area. Fast forward to present day and the now ten-page directory features ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
(Date:12/5/2016)... -- Sanovas, Inc., a life science asset holding ... its wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed ... - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology: